Relapse or worsening of chronic spontaneous urticaria during SARS-CoV-2 infection and vaccination in children: A telemedicine follow-up
Main Article Content
Keywords
Children, Chronic Spontaneous Urticaria, Second-generation Non-sedating Antihistamine, COVID-19, Telemedicine
Abstract
Background: Chronic urticaria (CU), characterized by daily wheals and/or angioedema lasting more than 6 weeks, is a common skin disease. CU is classified as spontaneous or inducible. Because of Coronavirus Disease-19 (COVID-19) pandemic, face-to-face visits were reduced, and many centers started remote consultations to minimize hospital admissions and risk for viral diffusion. Telemedicine became a valuable tool for evaluating and monitoring patients with chronic diseases, such as CU. This study aims to evaluate the effectiveness of telemedicine as a means for the follow-up of patients with chronic spontaneous urticaria (CSU) during the COVID-19 pandemic. In particular, we collected data related to CSU evolution and treatment by remote consultation. Moreover, we specifically investigated the impact of SARS-CoV-2 infection or vaccination on CSU in relapsing or worsening of such a disease.
Methods: The electronic charts were reviewed for patients diagnosed with CSU, who were referred to the allergy unit of Meyer Children’s Hospital, Florence. For each patient, a review of demographic characteristics, diagnostic workup, efficacy, and tolerability of the treatment was performed. Patients with a physical agent triggering CU were excluded from the study. Disease activity was monitored using the Urticaria Activity Score (UAS7). In addition, when the COVID-19 pandemic started, follow-up continued through telemedicine after an initial face-to-face visit when possible. Approximately 1 year after the diagnosis of CSU, patients were recontacted to investigate whether they had experienced a relapse or worsening of urticaria during a possible COVID-19 or immediately after receiving a COVID-19 vaccine.
Results: From January 2020 to March 2021, 84 cases of CSU were identified, with 71 (84.5%) of these being evaluated via televisit (remote consultation). During the remote follow-up period, 38/71 (53.5%) patients who were evaluated via televisit recovered completely from CSU, while 24 (33.8%) made therapy adjustments, and 9 (12.7%) had to discontinue follow-up through remote visits and return to face-to-face visits. In February 2022, we recontacted the 71 patients with CSU, and 50 (70.4%) of them answered by phone call interview. Four (19.2%) of the 26 patients who had COVID-19 showed CSU relapse, while 1 (3.8%) had a CSU worsening. Instead, 1 (3.8%) patient of the 26 who were vaccinated had a relapse of CSU, and 1 (3.8%) had a worsening of CSU, both after the first dose.
Conclusion: Our data showed that telemedicine can be an effective tool for the follow-up of patients with CSU. Moreover, COVID-19, as well as COVID-19 vaccination, may trigger CSU relapse or worsening, but both are unspecific triggers, and urticaria shows a very short duration in most cases.
References
2. Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy Eur J Allergy Clin Immunol. 2020;75(2):423–32. 10.1111/all.14037
3. Caffarelli C, Paravati F, El Hachem M, Duse M, Bergamini M, Simeone G, et al. Management of chronic urticaria in children: A clinical guideline. Ital J Pediatr. 2019;45(1):101. 10.1186/s13052-019-0695-x
4. Kocatürk E, Salman A, Cherrez-Ojeda I, Criado PR, Peter J, Comert-Ozer E, et al. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy Eur J Allergy Clin Immunol. 2021;76(3):816–30. 10.1111/all.14687
5. Smith AC, Thomas E, Snoswell CL, Haydon H, Mehrotra A, Clemensen J, et al. Telehealth for global emergencies: Implications for coronavirus disease 2019 (COVID-19). J Telemed Telecare. 2020;26(5):309–13. 10.1177/1357633X20916567
6. Bloem BR, Dorsey ER, Okun MS. The coronavirus disease 2019 crisis as catalyst for telemedicine for chronic neurological disorders. JAMA Neurol. 2020;77(8):927–8. 10.1001/jamaneurol.2020.1452
7. Utility of telemedicine in the COVID-19 era. Rev Cardiovasc Med. 2020;21(4):583–7. 10.31083/j.rcm.2020.04.188
8. Ohannessian R, Duong TA, Odone A. Global telemedicine implementation and integration within health systems to fight the COVID-19 pandemic: A call to action. JMIR Public Health Surveill. 2020;6(2):e18810. 10.2196/18810
9. Vidal-Alaball J, Acosta-Roja R, PastorHernández N, SanchezLuque U, Morrison D, NarejosPérez S, et al. Telemedicine in the face of the COVID-19 pandemic. Aten Primaria. 2020;52(6):418–22. 10.1016/j.aprim.2020.04.003
10. Morey-Olivé M, Espiau M, Mercadal-Hally M, Lera-Carballo E, García-Patos V. Cutaneous manifestations in the current pandemic of coronavirus infection disease (COVID 2019). An Pediatría (English Ed). 2020;92(6):374–5. 10.1016/j.anpede.2020.04.002
11. Muntean IA, Pintea I, Bocsan IC, Dobrican CT, Deleanu D. Covid-19 disease leading to chronic spontaneous urticaria exacerbation: A romanian retrospective study. Healthc. 2021;9(9):1144. 10.3390/healthcare9091144
12. Kempuraj D, Selvakumar GP, Ahmed ME, Raikwar SP, Thangavel R, Khan A, et al. COVID-19, Mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist. 2020;26(5–6):402–14. 10.1177/1073858420941476
13. Theoharides TC. Potential association of mast cells with coronavirus disease 2019. Ann Allergy, Asthma Immunol. 2021;126(3):217–8. 10.1016/j.anai.2020.11.003
14. Kritas SK, Ronconi G, Caraffa A, Gallenga CE, Ross R, Conti P. Mast cells contribute to coronavirus-induced inflammation: New anti-inflammatory strategy. J Biol Regul Homeost Agents. 2020;34(1):9–14. 10.23812/20-Editorial-Kritas
15. Hafezi B, Chan L, Knapp JP, Karimi N, Alizadeh K, Mehrani Y, et al. Cytokine storm syndrome in sars‐cov‐2 infections: A functional role of mast cells. Cells. 2021;10(7):1761. 10.3390/cells10071761
16. Criado PR, Pagliari C, Criado RFJ, Marques GF, Belda W. What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2? Dermatol Ther. 2020;33(6):e14068. 10.1111/dth.14068
17. Marshall JS, Portales-Cervantes L, Leong E. Mast cell responses to viruses and pathogen products. Int J Mol Sci. 2019;20(17):4241. 10.3390/ijms20174241
18. Sarti L, Barni S, Giovannini M, Liccioli G, Novembre E, Mori F. Efficacy and tolerability of the updosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria. Pediatr Allergy Immunol. 2021;32(1):153–60. 10.1111/pai.13325
19. Keswani A, Brooks JP, Khoury P. The future of telehealth in allergy and immunology training. J Allergy Clin Immunol Pract. 2020;8(7):2135–41. 10.1016/j.jaip.2020.05.009
20. Giovannini M, Lodi L, Sarti L, Guarnieri V, Barni S, Canessa C, et al. Pediatric allergy and immunology practice during the COVID-19 pandemic in Italy: Perspectives, challenges, and opportunities. Front Pediatr. 2020;8:565039. 10.3389/fped.2020.565039
21. González-Pérez R, Sánchez-Machín I, Poza-Guedes P, Matheu V, Álava-Cruz C, Mederos Luís E. Pertinence of telehealth in a rush conversion to virtual allergy practice during the covid-19 outbreak. J Investig Allergol Clin Immunol. 2021;31(1):78–80. 10.18176/jiaci.0597
22. Pattini S, Malizia V, Travaglini A, Brighetti MA, Della Giustina A, Sfika I, et al. Telemedicine for allergic patients during COVID-19. Pediatr Allergy Immunol. 2020;31 Suppl 26(Suppl 26):102–4. 10.1111/pai.13346
23. Anthony B Jr. Use of telemedicine and virtual care for remote treatment in response to COVID-19 pandemic. J Med Syst. 2020;44(7):132. 10.1007/s10916-020-01596-5
24. Mustafa SS, Vadamalai K, Ramsey A. Patient satisfaction with in-person, video, and telephone allergy/immunology evaluations during the COVID-19 pandemic. J Allergy Clin Immunol Pract. 2021;9(5):1858–63. 10.1016/j.jaip.2021.01.036
25. Abrams EM, Singer AG, Shaker M, Greenhawt M. What the COVID-19 pandemic can teach us about resource stewardship and quality in health care. J Allergy Clin Immunol Pract. 2021;9(2):608–12. 10.1016/j.jaip.2020.11.033
26. Imbalzano E, Casciaro M, Quartuccio S, Minciullo PL, Cascio A, Calapai G, et al. Association between urticaria and virus infections: A systematic review. Allergy Asthma Proc. 2016;37(1):18–22. 10.2500/aap.2016.37.3915
27. Dreyfus DH. Serological evidence that activation of ubiquitous human herpesvirus-6 (HHV-6) plays a role in chronic idiopathic/spontaneous urticaria (CIU). Clin Exp Immunol. 2016;183(2):203–8. 10.1111/cei.12704
28. Català A, Muñoz-Santos C, Galván-Casas C, Roncero Riesco M, Revilla Nebreda D, Solá-Truyols A, et al. Cutaneous reactions after SARS-CoV-2 vaccination: A cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. 2022;186(1):142–52. 10.1111/bjd.20639
29. McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46–55. 10.1016/j.jaad.2021.03.092
30. Grieco T, Ambrosio L, Trovato F, Vitiello M, Demofonte I, Fanto M, et al. Effects of vaccination against COVID-19 in chronic spontaneous and inducible urticaria (CSU/CIU) patients: A monocentric study. J Clin Med. 2022;11(7):1822. 10.3390/jcm11071822
31. Alflen C, Birch K, Shilian R, Wu SS, Hostoffer R. Two cases of well controlled chronic spontaneous urticaria triggered by the Moderna COVID-19 vaccine. Allergy Rhinol. 2021;12: 21526567211026271. 10.1177/21526567211026271
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.